Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
02 Gennaio 2024 - 1:00PM
Business Wire
Distinguished honour for Exscientia’s founder
and Chief Executive
Awarded in the 2024 New Year Honours List by HM
King Charles III
Follows multiple recent recognitions for
outstanding personal achievements and those of Exscientia
Professor Andrew Hopkins FRS FMedSci, founder and Chief
Executive of Exscientia plc (Nasdaq: EXAI), has been appointed
Commander of the Order of the British Empire (CBE) for services to
Science and Innovation by His Majesty King Charles III. The
distinguished honour comes as part of HM The King’s 2024 New Year
Honours List, recognising the achievements and service of
extraordinary people across the UK who have been recommended by the
Prime Minister based on an independent assessment process.
The appointment reflects Andrew’s life-long passion for
harnessing the power of innovative technologies to discover and
develop high-quality medicines to benefit patients. This
recognition follows multiple previous awards and prestigious
honours recently received by both Andrew and Exscientia, the
AI-driven precision medicine company he leads.
After publishing pioneering scientific papers on how machine
learning and generative algorithms could be used to design novel
drug leads, Andrew founded Exscientia in 2012 to create and develop
the best possible drugs in the fastest and most effective manner.
As the company’s CEO, Andrew led the group who discovered the first
AI-designed drugs to enter human clinical trials. Today, he heads a
global team of around 450 scientists and technology experts based
in Oxford, UK, and globally. Prior to Exscientia, Andrew held the
Chairs of Medicinal Informatics and Translational Biology at the
University of Dundee and spent a decade at Pfizer Inc. leading
various informatics groups. He received his doctorate in biophysics
from the University of Oxford and his LLD from the University of
Dundee where he also holds an Honorary Chair.
For its end-to-end AI-driven precision medicine platform,
Exscientia won the Prix Galien USA for Best Digital Health Solution
in late 2022, as well as the Prix Galien UK in the same category in
May 2023. Also in May this year, Andrew was elected for life to two
of the UK’s national academies in recognition of “exceptional
contributions to science”, as Fellow of the Royal Society, the
world’s oldest independent academic scientific body, and as Fellow
of the Academy of Medical Sciences. In September, Andrew was
featured on the inaugural TIME 100 AI list of most influential
people in AI, while most recently, in November 2023, Exscientia was
named to the inaugural Fortune 50 AI Innovators list.
“I’m truly humbled by this extraordinary recognition of the work
of my outstanding team that I am privileged to lead,” said Andrew.
“Our goal at Exscientia of utilising advanced technology to
accelerate the design of new drugs, an idea that originated during
my doctorate, has gained substantial momentum in changing the way
future therapies may be created, evaluated and brought to patients
in need of fast, effective and affordable treatment. Based on our
progress so far, we believe all drugs will be designed and
developed with AI and that this approach holds the key to
transforming the trajectory of human health forever.”
About Exscientia
Exscientia is an AI-driven precision medicine company committed
to discovering, designing and developing the best possible drugs in
the fastest and most effective manner. Exscientia developed the
first-ever functional precision oncology platform to successfully
guide treatment selection and improve patient outcomes in a
prospective interventional clinical study, as well as to progress
AI-designed small molecules into the clinical setting. Our internal
pipeline is focused on leveraging our precision medicine platform
in oncology, while our partnered pipeline broadens our approach to
other therapeutic areas. By pioneering a new approach to medicine
creation, we believe the best ideas of science can rapidly become
the best medicines for patients. Visit us at
https://www.exscientia.ai or follow us on Twitter
@exscientiaAI.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102661842/en/
Investor Relations: Sara Sherman investors@exscientia.ai
Media & Photos: Oliver Stohlmann media@exscientia.ai
Grafico Azioni Exscientia (NASDAQ:EXAI)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Exscientia (NASDAQ:EXAI)
Storico
Da Mag 2023 a Mag 2024